Antibody-drug conjugates (ADCs) consist of recombinant monoclonal antibodies (mAbs) that are covalently bound to cytotoxic chemicals via synthetic linkers. ADCs take advantage of the specificity of mAbs to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells. Antibody drug conjugates are one of the fastest growing classes of oncology therapeutics. In 2011, Seattle Genetics/Takeda’s Adcetris (brentuximab vedotin) was approved for treating Hodgkin lymphoma and anaplastic large cell lymphoma, whereas in 2013, Roche’s Kadcyla (trastuzumab emtansine) was approved for the treatment of breast cancer. The approvals have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation ADCs led second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody. Later, the lessons learned during the past decade are now being used in the development of third-generation ADCs, which involved strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues. Advancements over the past several decades have led to a new generation of ADCs comprising non-immunogenic mAbs, linkers with balanced stability and highly potent cytotoxic agents. In the recent years, ADC development platforms have matured sufficiently for multiple ADCs to gain regulatory approval, with several also close to market and a deep pipeline in development. In addition to the FDA-approved ADCs, there are several compounds are in late-stage clinical testing for both hematological and solid tumor indications.
The global antibody drug conjugates market segmentation is based on marketed drugs – Adcetris or SGN-35 (Brentuximab vedotin), Kadcyla or T-DM1 (Trastuzumab emtansine), and pipeline drugs – Rova-T or SC16LD6.5 (Rovalpituzumab tesirine), CDX‑011 (Glembatumumab vedotin), Besponsa or CMC-544 (Inotuzumab ozogamicin), IMGN853 (Mirvetuximab soravtansine), SGN‑CD33A (Vadastuximab talirine).
The global antibody drug conjugates market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global antibody drug conjugates market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global antibody drug conjugates market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global antibody drug conjugates market and profiled in this report include AbbVie, Agensys, Inc., Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Immunomedics, Inc., NBE-Therapeutics, Novartis AG, Pfizer, Sanofi, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.